Skip to main content
. 2020 Jun 4;81(3):420–426. doi: 10.1016/j.jinf.2020.05.067

Fig. 2.

Fig. 2

Seroprevalence analysis of SARS-CoV-2 with EIA assay and microneutralization assay. (A) The detection of IgM and IgG humoral responses against RBD and NP protein were detected by using sera samples diluted at 1:20 using EIA assay. Dashed blue line indicated cut-off value for each EIA assay, which was determined based on archived serum samples collected before COVID-19 outbreak. Sera from healthy controls (HC) collected in 2019 and the non-COVID-19 pneumonia patients were included as negative control, whereas 60 samples collected at different time points from 20 COVID-19 patients were used as positive control. Serum samples were collected on 14th day of the quarantine from 105 HCWs and they were also tested to determine IgM and IgG responses for RBD and NP protein. (B) The correlation analysis between anti-NP IgM and OD450nm-620nm value of anti-RBD IgM (left panel) and the correlation analysis between anti-NP IgG and OD450nm-620nm value of anti-RBD IgG (right panel). (C) The correlation analysis between the neutralization percentage of serum and anti-NP IgG (left panel) and the correlation analysis between the neutralization percentage of serum and OD450nm-620nm value of anti-RBD IgG (right panel). OD450nm-620nm = optical density at 450nm-620nm. NP = nucleoprotein. RBD = receptor-binding domain.